Nucleus Network
Nucleus Network is an Australian CRO specializing in early-phase clinical trials for pharmaceutical and biotechnology companies. The company leverages Australia's fast-track Clinical Trial Notification Scheme and has expanded into the UK via the Hammersmith Medicines Research acquisition.
- Company typePrivate
- Founded2004
- HeadquartersMelbourne, Australia
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What Nucleus Network does
Nucleus Network is an Australian Contract Research Organization (CRO) founded in 2004 and headquartered in Melbourne, specializing in the conduct of early-phase clinical trials. The company serves pharmaceutical and biotechnology companies as its primary customer segment, with secondary engagement of academic and institutional research organizations. Its core offering centers on Phase I and early-phase clinical research execution, with particular domain expertise in vaccines, therapeutics, and tropical disease research including tuberculosis, dengue, and malaria. Nucleus Network operates within Australia's Clinical Trial Notification Scheme, which enables 4-8 week regulatory approval timelines, providing a structural speed advantage for sponsor drug development programs.
The company generates revenue through professional services fees for clinical trial execution on a per-study basis, with pricing negotiated quote-by-quote rather than published. As a wholly-owned portfolio company of Blackstone, Nucleus Network has pursued growth through M&A, including the 2019 acquisition of Prism Clinical Research and the August 2025 acquisition of UK-based Hammersmith Medicines Research Ltd, which extended operations beyond Australia into the United Kingdom. The company engages in event-driven go-to-market activity, notably through participation in industry conferences such as BioAsia 2026 in Hyderabad, where it positioned itself alongside the Queensland Government delegation as a strategic partner for India-Australia biotech collaboration. As of early 2026, Blackstone is evaluating a potential sale of Nucleus Network as part of its portfolio diversification strategy.
Nucleus Network firmographics
Firmographics- Name
- Nucleus Network
- Legal name
- Nucleus Network
- Website
- https://nucleusnetwork.com.au
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Nucleus Network is an Australian CRO specializing in early-phase clinical trials for pharmaceutical and biotechnology companies. The company leverages Australia's fast-track Clinical Trial Notification Scheme and has expanded into the UK via the Hammersmith Medicines Research acquisition.
- Ownership category
- akta.pro rank
Nucleus Network industry classification
Industry- Product category
- Contract Research Organization (CRO) / Early-Phase Clinical Trial Services
- NAICS
- Medical Laboratories (621511), Scientific Research and Development Services (5417)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
Keywords
Where Nucleus Network is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Markets served
Nucleus Network business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Research Services: Nucleus Network operates as a Contract Research Organization (CRO), providing clinical trial services to pharmaceutical and biotechnology companies. Revenue is generated through service fees for conducting clinical research trials.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Nucleus Network product offering
Product offeringCore offering
Nucleus Network operates as a Contract Research Organization (CRO) conducting Phase I and early-phase clinical trials for pharmaceutical and biotechnology companies. Services are delivered from Australia-based facilities with access to the Clinical Trial Notification Scheme, enabling 4-8 week trial approval timelines. The company specializes in vaccine and therapeutics clinical research, including tropical disease studies for tuberculosis, dengue, and malaria.
Product overview
Nucleus Network is a Contract Research Organization (CRO) specializing in early-phase clinical trials. Based in Australia, the company conducts Phase I and early-phase clinical research for pharmaceutical and biotechnology companies. The company is noted for fast clinical trial approval pathways and expertise in tropical health research, vaccines, and therapeutics for diseases such as tuberculosis, dengue, and malaria. Nucleus Network serves as a strategic partner for biotech collaboration between Australia and international markets.
Differentiator
Problem solved
Functional benefit
Products and services
- Early-Phase Clinical Trial Services Contract Research Organization (CRO) services delivering Phase I and early-phase clinical trials for pharmaceutical and biotechnology sponsors, leveraging Australia's Clinical Trial Notification Scheme for accelerated 4-8 week approvals.
- Vaccines and Therapeutics Clinical Research Clinical research services focused on vaccine and therapeutics development programs for pharmaceutical and biotechnology sponsors.
- Tropical Disease Clinical Research Specialized clinical research services for tropical disease drug and vaccine development, covering tuberculosis, dengue, and malaria.
Companies that use Nucleus Network
Customer profileSegments2 records
Ideal customer profiles2 records
Nucleus Network technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Nucleus Network partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Queensland Government and Industry DelegationcoreQueensland positioned itself as a strategic partner for Indian companies in life sciences and biotechnology collaboration at BioAsia 2026. Nucleus Network participated as part of Queensland delegations, outlining areas of convergence in clinical research, vaccines, and therapeutics for tropical diseases.
Scale indicators2 records
Recent moves5 records
Expansion highlights5 records
Nucleus Network competitors and assessment
Company assessmentBroad incumbents
- Parexel International: Global full-service CRO with established early-phase clinical pharmacology units. Competes with Nucleus Network for biotech and pharma Phase I contracts, particularly cross-region programs.
- Syneos Health: Global biopharmaceutical solutions organization with early-phase clinical services. Competes with Nucleus Network for Phase I biotech contracts and broader clinical development mandates.
- ICON plc: Global CRO offering Phase I–IV clinical research services including early-phase units. Competes with Nucleus Network for Phase I biotech programs and large pharma outsourcing relationships.
- Medpace: Mid-sized global CRO with growing early-phase franchise and a biotech-focused commercial model. Comparable to Nucleus Network on Phase I work for emerging biotech sponsors.
- IQVIA: Largest global CRO with Phase I–IV capabilities and broad biotech/pharma sponsor relationships. Overlaps with Nucleus Network on early-phase work but operates at vastly larger scale across the full clinical development lifecycle.
- Wuxi AppTec: China-headquartered global CRO/CDMO with early-phase and preclinical capabilities. Competes with Nucleus Network on APAC biotech Phase I programs and on global biotech outsourcing mandates.
Direct peers
- George Clinical: APAC-headquartered CRO with strong early-phase and late-phase operations, particularly in Australia and Asia. Directly comparable to Nucleus Network on regional Phase I capabilities and APAC biotech sponsors.
- Charles River Laboratories: Global CRO with a leading early-phase / Phase I clinical services business. Highly comparable to Nucleus Network on core Phase I offering, sponsor base (biotech and large pharma), and early-phase scientific capabilities.
- Linear Clinical Research: Australia-based early-phase clinical trial specialist operating out of Perth. Directly competes with Nucleus Network on Australian Phase I studies for biotech and pharma sponsors.
- Novotech: APAC-focused full-service CRO with strong early-phase presence across Australia and Asia. Competes head-to-head with Nucleus Network for regional biotech Phase I studies and shares similar sponsor overlap.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Nucleus Network social profiles
Digital presenceNucleus Network financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nucleus Network leadership team
Management profileNumber of profiles
Profiles2 records
Nucleus Network funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nucleus Network M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nucleus Network
What does Nucleus Network do?
Nucleus Network operates as a Contract Research Organization (CRO) conducting Phase I and early-phase clinical trials for pharmaceutical and biotechnology companies. Services are delivered from Australia-based facilities with access to the Clinical Trial Notification Scheme, enabling 4-8 week trial approval timelines. The company specializes in vaccine and therapeutics clinical research, including tropical disease studies for tuberculosis, dengue, and malaria.
Is Nucleus Network a public or private company?
Nucleus Network is a private company. It is classified as private equity controlled and is currently operating.
When was Nucleus Network founded?
Nucleus Network was founded in 2004. It employs 501 to 1,000 people.
Where is Nucleus Network based?
Nucleus Network is headquartered in Melbourne, Australia, in the Oceania region.
How does Nucleus Network make money?
One revenue line is on record: clinical Research Services.
Who are Nucleus Network's main competitors?
Broad incumbents on record are Parexel International, Syneos Health, ICON plc, Medpace, IQVIA and Wuxi AppTec. Direct peers are George Clinical, Charles River Laboratories, Linear Clinical Research and Novotech.
Does Nucleus Network have an API?
No public API is recorded for Nucleus Network.
What industry is Nucleus Network in?
Nucleus Network's product category is Contract Research Organization (CRO) / Early-Phase Clinical Trial Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 621511 and its SIC code is 8071.